Early diagnosis and immediate intervention are challenging demands for those who care for patients with rheumatoid arthritis. Early therapy can prevent irreversible damages and provides optimal conditions for favourable prognosis and slowed progression of the dis-ease. But in early stages the symptoms are rather unspecific, therefore many patients show up too late at the rheumatology specialist – at an average not until one and a half years have passed after the first symptoms occurred. At this time, the window of opportu-nity, the optimum time for starting a therapy is closed again.
rheumachec® offers the opportunity to fill this gap. In case of suspected disease every resident doctor and even the patient himself can easily perform the test and get fast and reliable information in only 15 minutes.
rheumachec® needs only one drop of whole blood – laborious preparation of serum is not required.
rheumachec® combines two established biomarkers for rheumatoid arthritis: rheumatoid factor and mutated citrullinated Vimentin.
Rheumatoid factor is a well-known marker for rheumatic diseases and the only laboratory parameter included in the official ACR-criteria for diagnosis of rheumatoid arthritis, al-though antibodies to rheumatoid factor have only limited specificity for rheumatoid arthritis. They can also be detected in other rheumatic or inflammatory diseases and sometimes in healthy people. Therefore only patients who tested negative for Rheumatoid factor can be sure of not suffering from rheumatoid arthritis.
Auto-antibodies to MCV are even more than highly specific markers for rheumatoid arthri-tis. They indicate a severe course of the disease and moreover their titers correspond to disease activity. In addition they occur already in early stages of the disease even before characteristic symptoms become evident.
Meet us in hall 3, booth A31 and get to know the world novelty rheumachec®!
ORGENTEC Diagnostika GmbH
Tel. +49 6131 9258-0
Fax +49 6131 9258-58